Abstract

BK002 consists of Achyranthes japonica Nakai (AJN) and Melandrium firmum Rohrbach (MFR) that have been used as herbal medicines in China and Korea. AJN and MFR have been reported to have anti-inflammatory, anti-oxidative, and anti-cancer activities, although the synergistic targeting multiple anti-cancer mechanism in castration-resistant prostate cancer (CRPC) has not been well reported. However, the drug resistance and transition to the androgen-independent state of prostate cancer contributing to CRPC is not well studied. Here, we reported that BK002 exerted cytotoxicity and apoptosis in CRPC PC3 cell lines and prostate cancer DU145 cell lines examined by cytotoxicity, western blot, a LIVE/DEAD cell imaging assay, reactive oxygen species (ROS) detection, quantitative real-time polymerase chain reaction (RT-PCR), and transfection assays. The results from our investigation found that BK002 showed more cellular cytotoxicity than AJN and MFR alone, suggesting that BK002 exhibited potential cytotoxic properties. Consistently, BK002 increased DNA damage, and activated p-γH2A.X and depletion of survivin-activated ubiquitination of pro-PARP, caspase9, and caspase3. Notably, live cell imaging using confocal microscopy found that BK002 effectively increased DNA-binding red fluorescent intensity in PC3 and DU145 cells. Also, BK002 increased the anti-proliferative effect with activation of the C/EBP homologous protein (CHOP) and significantly attenuated PI3K/AKT expression. Notably, BK002-treated cells increased ROS generation and co-treatment of N-Acetyl-L-cysteine (NAC), an ROS inhibitor, significantly preventing ROS production and cellular cytotoxicity, suggesting that ROS production is essential for initiating apoptosis in PC3 and DU145 cells. In addition, we found that BK002 significantly enhanced miR-192-5p expression, and co-treatment with BK002 and miR-192-5p inhibitor significantly reduced miR-192-5p expression and cellular viability in PC3 and DU145 cells, indicating modulation of miR-192-5p mediated apoptosis. Finally, we found that BK002-mediated CHOP upregulation and PI3K downregulation were significantly reduced and restrained by miR-192-5p inhibitor respectively, suggesting that the anti-cancer effect of BK002 is associated with the miR-192-5p/PI3K/CHOP pathway. Therefore, our study reveals that a combination of AJN and MFR might be more effective than single treatment against apoptotic activities of both CRPC cells and prostate cancer cells.

Highlights

  • Prostate cancer (PC) is a malignant cancer that represents the second highest death rate of male cancer worldwide, with 1.3 million new cases and 359,000 mortalities in 2018 (3.8% of cancer deaths) [1, 2]

  • The HPLC chromatograms showed the existence of b-ecdysterone (Rt = 28.36 min) in BK002 by comparison with retention time (Rt) and photodiode array (PDA) spectrum of the standard solution (Figure 1)

  • We found that the Melandrium firmum Rohrbach (MFR) and Achyranthes japonica Nakai (AJN) b-ecdysterone peak was very small (Figures 1B–D), b-ecdysterone exhibited more cellular cytotoxicity in normal MDBK cells than prostate cancer PC and DU145 cells (Figure 1E), suggesting that b-ecdysterone has no toxic effects on cancer cells

Read more

Summary

Introduction

Prostate cancer (PC) is a malignant cancer that represents the second highest death rate of male cancer worldwide, with 1.3 million new cases and 359,000 mortalities in 2018 (3.8% of cancer deaths) [1, 2]. Prostate cancer can become castrationresistant prostate cancer (CRPC) after recurrence due to hormone deprivation therapy [3]. CRPC is classified by intracrine/paracrine androgen secretion due to resistance acquired after testosterone deprivation therapy [4]. The mortality rate rapidly progressed to a 50% rise in CRPC [6]. The mortality rate of CRPC is still high [8]. Many researchers had conducted studies for novel therapies for CRPC by 2020 [5]. Abiraterone acetate (AA, Zytiga) and enzalutamide (Xtandi) are hormone inhibitors that have been approved by the Food and Drug Administration (FDA) for treatment of CRPC. That is why the necessity of discovering a new biomarker has increased for CRPC [6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call